Together with previous work suggesting GDE2 dysfunction in AD and ALS/FTD patients, our observations provide behavioral evidence supporting GDE2 contributions to neurodegenerative phenotypes associated with disease. This evidence concerns the gene GDPD5 and amyotrophic lateral sclerosis.